首页 > 最新文献

Digestive Endoscopy最新文献

英文 中文
Cricopharyngeal Per Oral Endoscopic Myotomy (C-POEM) With a Novel Therapeutic Gastroscope 环咽经口内镜肌切开术(C-POEM)与一种新型治疗性胃镜。
IF 4.7 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-07-30 DOI: 10.1111/den.70003
Niroshan Muwanwella, Krish Ragunath

Endoscopic cricopharyngeal myotomy (C-POEM) is an evolving, minimally invasive technique for treating cricopharyngeal dysfunction [1, 2], which may result from conditions such as idiopathic cricopharyngeal bar, Parkinson's Disease, or Inclusion Body Myositis. The procedure is technically challenging due to the confined space of the hypopharynx (Figure 1). Traditionally, C-POEM is performed using a standard gastroscope, which has a 9.9 mm outer diameter and a 2.3 mm working channel. With the addition of a conical distal attachment cap, a mucosal incision of approximately 15 mm is typically required to access the submucosal space, further complicating the procedure in anatomically restricted areas. We present a video case demonstrating the use of a next-generation slim therapeutic gastroscope—the Fujifilm EG-840TP—in a successful C-POEM. This scope introduces several important technical improvements: Slimmer outer diameter: 7.9 mm versus 9.9 mm (standard scope), allowing easier maneuverability in the hypopharynx and proximal esophagus; larger working channel: 3.2 mm versus 2.3 mm, enabling the simultaneous use of instruments and suction; smaller mucosal incision required: A 10 mm mucosal incision is sufficient, even with the distal cap in place; and enhanced tip angulation of 210° upward and 160° downward flexion, improving access and precision in tight anatomical spaces (Figure 2). These design enhancements facilitate safer and more efficient dissection, improve procedural control, and reduce tissue trauma. A conical cap (DH-083ST—FujiFilm, Japan) with a 3.5 mm distal stiff section from the tip of the gastroscope and a 7 mm inner diameter of the distal end was also used for the C-POEM. Our case highlights the feasibility, safety, and therapeutic potential of the EG-840TP in upper esophageal interventions [3, 4], suggesting that it may set a new standard for C-POEM and similar endoscopic procedures in narrow anatomical regions.

Niroshan Muwanwella: conceptualization (lead), resources, writing – original draft (lead). Krish Ragunath: conceptualization (supporting), writing – review and editing.

Approval of the research protocol by an Institutional Reviewer Board: None.

Informed consent: Informed consent obtained from patient to publish de-identified endoscopic images and videos.

Registry and the registration no. of the study/trial: None.

Animal studies: None.

The authors declare no conflicts of interest. Prof Krish Ragunath is an Associate Editor of Digestive Endoscopy.

内镜环咽肌切开术(C-POEM)是一种不断发展的微创技术,用于治疗环咽功能障碍[1,2],这种功能障碍可能由特发性环咽阻滞、帕金森病或包涵体肌炎等疾病引起。由于下咽的狭窄空间,该手术在技术上具有挑战性(图1)。传统上,C-POEM使用标准胃镜进行,其外径为9.9 mm,工作通道为2.3 mm。随着锥形远端附着帽的增加,通常需要大约15mm的粘膜切口才能进入粘膜下空间,这使得解剖受限区域的手术更加复杂。我们展示了一个视频案例,展示了在一个成功的C-POEM中使用新一代超薄治疗胃镜-富士eg - 840tp。该瞄准镜引入了几项重要的技术改进:更细的外径:7.9毫米与9.9毫米(标准瞄准镜)相比,更容易在下咽和食管近端操作;更大的工作通道:3.2 mm vs 2.3 mm,可以同时使用仪器和吸力;需要更小的粘膜切口:10毫米的粘膜切口就足够了,即使远端帽已经到位;提高尖端角度210°向上和160°向下弯曲,提高狭窄解剖空间的接触和精度(图2)。这些设计的改进促进了更安全、更有效的解剖,改善了程序控制,减少了组织创伤。C-POEM也使用锥形帽(DH-083ST-FujiFilm, Japan),其远端僵硬部分距胃镜尖端3.5 mm,远端内径为7 mm。我们的病例强调了EG-840TP在上食管介入治疗中的可行性、安全性和治疗潜力[3,4],这表明它可能为狭窄解剖区域的C-POEM和类似的内镜手术树立新的标准。Niroshan Muwanwella:构思(导),资源,写作-原稿(导)。Krish Ragunath:概念化(支持),写作-审查和编辑。机构审查委员会批准研究方案:无。知情同意:获得患者发布去识别内镜图像和视频的知情同意。注册表及注册编号研究/试验:无。动物实验:没有。作者声明无利益冲突。Krish Ragunath教授是《消化内窥镜》杂志的副主编。
{"title":"Cricopharyngeal Per Oral Endoscopic Myotomy (C-POEM) With a Novel Therapeutic Gastroscope","authors":"Niroshan Muwanwella,&nbsp;Krish Ragunath","doi":"10.1111/den.70003","DOIUrl":"10.1111/den.70003","url":null,"abstract":"<p>Endoscopic cricopharyngeal myotomy (C-POEM) is an evolving, minimally invasive technique for treating cricopharyngeal dysfunction [<span>1, 2</span>], which may result from conditions such as idiopathic cricopharyngeal bar, Parkinson's Disease, or Inclusion Body Myositis. The procedure is technically challenging due to the confined space of the hypopharynx (Figure 1). Traditionally, C-POEM is performed using a standard gastroscope, which has a 9.9 mm outer diameter and a 2.3 mm working channel. With the addition of a conical distal attachment cap, a mucosal incision of approximately 15 mm is typically required to access the submucosal space, further complicating the procedure in anatomically restricted areas. We present a video case demonstrating the use of a next-generation slim therapeutic gastroscope—the Fujifilm EG-840TP—in a successful C-POEM. This scope introduces several important technical improvements: Slimmer outer diameter: 7.9 mm versus 9.9 mm (standard scope), allowing easier maneuverability in the hypopharynx and proximal esophagus; larger working channel: 3.2 mm versus 2.3 mm, enabling the simultaneous use of instruments and suction; smaller mucosal incision required: A 10 mm mucosal incision is sufficient, even with the distal cap in place; and enhanced tip angulation of 210° upward and 160° downward flexion, improving access and precision in tight anatomical spaces (Figure 2). These design enhancements facilitate safer and more efficient dissection, improve procedural control, and reduce tissue trauma. A conical cap (DH-083ST—FujiFilm, Japan) with a 3.5 mm distal stiff section from the tip of the gastroscope and a 7 mm inner diameter of the distal end was also used for the C-POEM. Our case highlights the feasibility, safety, and therapeutic potential of the EG-840TP in upper esophageal interventions [<span>3, 4</span>], suggesting that it may set a new standard for C-POEM and similar endoscopic procedures in narrow anatomical regions.</p><p><b>Niroshan Muwanwella:</b> conceptualization (lead), resources, writing – original draft (lead). <b>Krish Ragunath:</b> conceptualization (supporting), writing – review and editing.</p><p>Approval of the research protocol by an Institutional Reviewer Board: None.</p><p>Informed consent: Informed consent obtained from patient to publish de-identified endoscopic images and videos.</p><p>Registry and the registration no. of the study/trial: None.</p><p>Animal studies: None.</p><p>The authors declare no conflicts of interest. Prof Krish Ragunath is an Associate Editor of Digestive Endoscopy.</p>","PeriodicalId":159,"journal":{"name":"Digestive Endoscopy","volume":"37 11","pages":"1250-1251"},"PeriodicalIF":4.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/den.70003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144755256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Size Matters in Rectal Neuroendocrine Tumors: Redefining Risk Thresholds for Surveillance and Management 直肠神经内分泌肿瘤的大小问题:重新定义监测和管理的风险阈值。
IF 4.7 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-07-27 DOI: 10.1111/den.70006
Shinya Sugimoto, Hayato Nakagawa
<p>The widespread implementation of screening colonoscopy in recent years has led to a marked increase in detecting small asymptomatic rectal neuroendocrine tumors (NETs) [<span>1</span>]. Accumulating evidence from endoscopic observations, histopathological assessments of resected specimens, and longitudinal clinical follow-up has helped elucidate several risk factors for metastatic potential. These include central depression, tumor size, Ki-67 labeling index, mitotic count, and lymphovascular invasion (LVI) [<span>2, 3</span>]. The current clinical practice guidelines for managing localized rectal NETs demonstrate considerable regional variation, largely reflecting differing interpretations of metastatic risk. Prominent divergences are evident among international guidelines, particularly those issued by the European Neuroendocrine Tumor Society (ENETS) [<span>4</span>], National Comprehensive Cancer Network (NCCN) [<span>5</span>], and Japan Neuroendocrine Tumor Society (JNETS) [<span>6</span>]. Both the ENETS and NCCN guidelines primarily emphasize tumor size as the principal criterion for determining therapeutic strategy and surveillance protocols. In contrast, the JNETS guidelines advocate a more aggressive approach, even in relatively small-sized lesions. According to Western consensus, rectal NETs measuring 2.0 cm or less are generally considered suitable for local excision, either via endoscopic or transanal techniques. However, tumors exceeding 2.0 cm are regarded as clear indications for radical resection with regional lymphadenectomy. The NCCN, in particular, supports local excision of well-differentiated NETs in the 1.0–2.0 cm range, despite evidence suggesting a non-negligible incidence of lymph node metastasis in this subgroup. Similarly, the ENETS permits endoscopic resection of tumors within the 1.0–2.0 cm range, provided that there is no evidence of muscularis propria invasion or lymph node involvement on imaging. Radical surgical procedures such as total mesorectal excision are reserved for tumors exceeding 2.0 cm or those displaying high-risk pathological features.</p><p>In contrast, the JNETS guidelines recommend radical surgical resection—specifically, proctectomy with regional lymph node dissection—for any rectal NET measuring 1.0 cm or greater. This recommendation also applies to tumors classified as grade 2 (NET G2) according to the World Health Organization classification, neuroendocrine carcinomas (NECs), and lesions demonstrating signs of deep submucosal or muscular invasion. In essence, the Japanese criteria for oncologic resection adopt a lower threshold—based on either a tumor size of ≥ 1.0 cm or high histologic grade—reflecting a more precautionary and risk-averse clinical philosophy. These divergences in clinical approach have prompted ongoing debate. The Japanese strategy prioritizes eliminating even a modest risk of occult lymph node metastasis. However, this strategy might result in overtreatment in patients wit
近年来,筛查性结肠镜检查的广泛实施,使得小的无症状直肠神经内分泌肿瘤(NETs)[1]的检出率显著增加。从内窥镜观察、切除标本的组织病理学评估和纵向临床随访中积累的证据有助于阐明转移潜力的几个危险因素。这些指标包括中枢凹陷、肿瘤大小、Ki-67标记指数、有丝分裂计数和淋巴血管侵袭(LVI)[2,3]。目前的临床实践指南显示出相当大的地区差异,很大程度上反映了对转移风险的不同解释。国际指南之间存在明显的分歧,特别是欧洲神经内分泌肿瘤学会(ENETS)[4]、国家综合癌症网络(NCCN)[5]和日本神经内分泌肿瘤学会(JNETS)[6]发布的指南。ENETS和NCCN指南都主要强调肿瘤大小是确定治疗策略和监测方案的主要标准。相比之下,JNETS指南提倡更积极的方法,即使是相对较小的病变。根据西方共识,一般认为小于或等于2.0 cm的直肠NETs适合通过内镜或经肛技术进行局部切除。然而,超过2.0 cm的肿瘤被认为是根治性切除和局部淋巴结切除术的明确适应症。NCCN尤其支持1.0-2.0 cm范围内分化良好的NETs的局部切除,尽管有证据表明该亚组中淋巴结转移的发生率不可忽略。同样,ENETS允许内镜切除1.0-2.0 cm范围内的肿瘤,前提是影像学上没有固有肌层侵犯或淋巴结受累的证据。根治性手术,如全肠系膜切除,保留用于肿瘤超过2.0 cm或表现出高危病理特征。相比之下,JNETS指南推荐根治性手术切除——特别是直肠净淋巴结切除术和区域淋巴结清扫——对于任何大于1.0 cm的直肠净淋巴结。这一建议也适用于世界卫生组织分级为2级(NET G2)的肿瘤、神经内分泌癌(NECs)和有深部粘膜下或肌肉浸润征象的病变。本质上,日本肿瘤切除术的标准采用较低的阈值-基于肿瘤大小≥1.0 cm或高组织学分级-反映了更预防和规避风险的临床理念。这些临床方法上的分歧引发了持续的争论。日本的策略优先消除即使是适度的潜在淋巴结转移风险。然而,这种策略可能会导致风险最小的小的分化良好的肿瘤患者过度治疗。相比之下,西方指南强调通过限制小于2.0 cm的肿瘤的根治性手术来避免过度治疗,即使这需要接受低但临床相关的淋巴结传播风险。历史数据为这些不同的哲学提供了重要的背景。小于1.0 cm的直肠类癌通常与极低的转移发生率相关,而1.0 - 2.0 cm的直肠类癌则具有适度但明显升高的风险。相反,大于2.0 cm的肿瘤始终与淋巴结转移的可能性高相关。这些风险梯度有助于阐明区域指南阈值背后的基本原理。西方指南使用2.0 cm的临界值,隐含地接受1.0 - 2.0 cm病变相关的中间风险,支持器官保存和降低治疗相关的发病率。相反,日本的指南寻求在肿瘤大小超过1.0厘米或表现出侵袭性病理特征时,先发制人地解决转移风险上升的问题。在本期的《消化道内窥镜》杂志上,Kim等人的研究提供了有价值的数据,支持对当前直肠NETs基于尺寸的截止阈值进行关键的重新评估。利用1011名患者的大队列,作者提出了一个风险适应管理框架,结合肿瘤大小和生物学特征,如组织学分级,以实现更个性化的治疗策略。他们的发现为完善现有的分类系统提供了一个令人信服的理论基础,通过引入中间阈值来更精确地对复发风险进行分层。确定两个特定的肿瘤大小阈值,0.7和1.5厘米,是本研究最具影响力的贡献之一,它比1.0和2.0厘米的传统基准提供了更大的区分能力。0.7 cm阈值对于内镜切除治疗的G1肿瘤特别有意义。 值得注意的是,在随访期间,没有一个G1 NETs尺寸为0.7 cm或更小,切除边缘为阴性,没有LVI的证据,发生复发。这使得在该阈值下的复发预测达到100%的敏感性。这些发现表明,真正的小G1肿瘤(明显小于1.0 cm)具有极低的转移性扩散风险,在适当选择的病例中,可能不需要常规的切除后监测。先前的多中心研究结果支持0.7 cm阈值的生物学合理性,这些研究表明,0.6 cm或更小的直肠NETs与淋巴结转移无关,而0.7-1.0 cm的NETs约有10%的淋巴结受病灶[2,5]。因此,0.6-0.7 cm范围内的阈值似乎可以有效地将转移潜力可忽略的病变与那些尽管仍然很低但具有临床相关风险的病变区分开来。实际上,这可能意味着在完全切除0.5 cm G1 NET后,不需要进行密集的影像学随访。然而,0.9 cm或1.0 cm的病变,尽管比传统的1.0 cm切点小,但考虑到隐匿转移的可能性更高,可能需要更密切的观察甚至额外的治疗。第二个阈值为1.5 cm,来自手术治疗的G1伴LVI肿瘤的亚组分析。1.5 cm或更小的肿瘤没有复发,而只有大于1.5 cm的肿瘤才会复发。这些发现表明,对于这种大小的肿瘤,即使存在诸如LVI等不良病理特征,治疗性手术仍然是必不可少的。如果得到证实,这一阈值可能会加强术后风险分层。例如,伴有LVI但未累及淋巴结的1.2 cm G1 NET可能不需要辅助治疗或强化监测。相比之下,1.8 cm lvi阳性肿瘤可考虑高风险,可能受益于辅助治疗或密切的长期随访。重要的是,1.5厘米的阈值弥补了目前西方和日本治疗指南之间的差距。JNET指南建议对大于1.0 cm的肿瘤进行根治性手术;Kim等人的发现支持这种方法治疗1.5厘米的肿瘤。另一方面,西方的做法有时允许局部治疗1.5厘米的病变,现在可能需要重新评估,因为这个大小似乎接近手术治疗的上限。虽然Kim等人纳入了G2 NETs病例和少数nec病例,但数据仍然不足以得出治疗这些更高级别肿瘤的明确结论。该分析仅涉及35个G2 NETs和9个nec。作者报告说,G2肿瘤的预后比G1差,大约四分之一的肿瘤出现淋巴结转移,复发率和死亡率可能更高。然而,G2病例数量有限,仅占队列的3.5%,可能导致统计能力不足,无法在该亚组中进行有意义的风险分层。G2肿瘤是否会遵循与G1类似的大小相关的风险模式,或者是否所有的G2肿瘤,即使是非常小的肿瘤,都会有很大的风险,目前还不清楚。作者建议对所有G2 NETs进行定期随访,无论其大小,基本上将其视为一致的高风险。虽然这是一个谨慎而合理的结论,但未来需要对直肠G2肿瘤进行大规模研究或登记,以明确风险是否会因大小而变化,例如,0.5 cm的G2 NET是否真的与1.5 cm病变具有相同的风险。直肠NECs同样未被充分代表,仅包括9例。这些肿瘤很少见,但侵袭性很强,从目前的数据集无法得出有意义的结论。然而,观察到的不良结果使它们与G2肿瘤一致。需要进一步的研究来确定局部NEC的最佳治疗策略。目前,大多数临床指南根据其高级别组织学推断,并建议根治性手术和全身治疗,即使是小病变。综上所述,Kim等人提出的0.7 cm和1.5 cm的阈值为直肠小NETs患者的风险分层提供了一个具有临床意义的双层模型。尽管对于G2 NETs和nec等高级别肿瘤的数据仍然有限,但研究结果支持在真正低风险的G1肿瘤中采用更保守的治疗方法。具体而言,完全切除的G1肿瘤尺寸为0.7 cm或更小,边缘阴性且无LVI的患者可能不需要进行强化监测。然而,即使切除标本,在准确确定肿瘤是否会测量0时,也存在固有的局限性和潜在的困难。 通过病理评估,精确地将肿瘤分类为WHO G1或G2,或可靠地确定LVI bb0的存在或不存在。根据Pa
{"title":"Size Matters in Rectal Neuroendocrine Tumors: Redefining Risk Thresholds for Surveillance and Management","authors":"Shinya Sugimoto,&nbsp;Hayato Nakagawa","doi":"10.1111/den.70006","DOIUrl":"10.1111/den.70006","url":null,"abstract":"&lt;p&gt;The widespread implementation of screening colonoscopy in recent years has led to a marked increase in detecting small asymptomatic rectal neuroendocrine tumors (NETs) [&lt;span&gt;1&lt;/span&gt;]. Accumulating evidence from endoscopic observations, histopathological assessments of resected specimens, and longitudinal clinical follow-up has helped elucidate several risk factors for metastatic potential. These include central depression, tumor size, Ki-67 labeling index, mitotic count, and lymphovascular invasion (LVI) [&lt;span&gt;2, 3&lt;/span&gt;]. The current clinical practice guidelines for managing localized rectal NETs demonstrate considerable regional variation, largely reflecting differing interpretations of metastatic risk. Prominent divergences are evident among international guidelines, particularly those issued by the European Neuroendocrine Tumor Society (ENETS) [&lt;span&gt;4&lt;/span&gt;], National Comprehensive Cancer Network (NCCN) [&lt;span&gt;5&lt;/span&gt;], and Japan Neuroendocrine Tumor Society (JNETS) [&lt;span&gt;6&lt;/span&gt;]. Both the ENETS and NCCN guidelines primarily emphasize tumor size as the principal criterion for determining therapeutic strategy and surveillance protocols. In contrast, the JNETS guidelines advocate a more aggressive approach, even in relatively small-sized lesions. According to Western consensus, rectal NETs measuring 2.0 cm or less are generally considered suitable for local excision, either via endoscopic or transanal techniques. However, tumors exceeding 2.0 cm are regarded as clear indications for radical resection with regional lymphadenectomy. The NCCN, in particular, supports local excision of well-differentiated NETs in the 1.0–2.0 cm range, despite evidence suggesting a non-negligible incidence of lymph node metastasis in this subgroup. Similarly, the ENETS permits endoscopic resection of tumors within the 1.0–2.0 cm range, provided that there is no evidence of muscularis propria invasion or lymph node involvement on imaging. Radical surgical procedures such as total mesorectal excision are reserved for tumors exceeding 2.0 cm or those displaying high-risk pathological features.&lt;/p&gt;&lt;p&gt;In contrast, the JNETS guidelines recommend radical surgical resection—specifically, proctectomy with regional lymph node dissection—for any rectal NET measuring 1.0 cm or greater. This recommendation also applies to tumors classified as grade 2 (NET G2) according to the World Health Organization classification, neuroendocrine carcinomas (NECs), and lesions demonstrating signs of deep submucosal or muscular invasion. In essence, the Japanese criteria for oncologic resection adopt a lower threshold—based on either a tumor size of ≥ 1.0 cm or high histologic grade—reflecting a more precautionary and risk-averse clinical philosophy. These divergences in clinical approach have prompted ongoing debate. The Japanese strategy prioritizes eliminating even a modest risk of occult lymph node metastasis. However, this strategy might result in overtreatment in patients wit","PeriodicalId":159,"journal":{"name":"Digestive Endoscopy","volume":"37 11","pages":"1224-1226"},"PeriodicalIF":4.7,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/den.70006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic Transpapillary Gallbladder Drainage for Gangrenous Cholecystitis: A Minimally Invasive Approach Under Scrutiny 内镜下经乳头胆囊引流治疗坏疽性胆囊炎:一种微创方法。
IF 4.7 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-07-25 DOI: 10.1111/den.70004
Yoshihide Kanno
<p>Gangrenous cholecystitis (GC) is a life-threatening form of acute cholecystitis characterized by full-thickness necrosis of the gallbladder wall. The pathogenesis involves ischemia and vascular compromise, typically resulting from prolonged inflammation, cystic artery obstruction, or elevated intraluminal pressure [<span>1</span>]. Histologically, GC is marked by transmural necrosis, hemorrhaging, and dense neutrophilic infiltration. The gallbladder wall may exhibit complete mucosal necrosis, vascular thrombosis, and, in some cases, intramural abscesses. These features underscore the severity of the disease and its high risk of complications, including perforation and peritonitis.</p><p>Emergency cholecystectomy remains the standard treatment for GC [<span>2</span>]. This is largely because decompression via gallbladder puncture (traditionally through a percutaneous route and more recently via endosonographically created routes) has been associated with a high risk of perforation. The friable wall of a gangrenous gallbladder lacks the structural integrity to secure a catheter, unlike resilient muscular tissue. Once punctured, the fragile cystic wall, which barely maintains its shape under high intraluminal pressure, may collapse irreparably.</p><p>In contrast, endoscopic transpapillary gallbladder drainage (ETGBD) offers a non-puncture alternative that could facilitate recovery in selected GC cases. If the gangrenous changes are barely reversible, non-puncture drainage may support conservative healing. Even when irreversible mucosal damage has occurred, the gallbladder may retain its structure following the resolution of inflammation, provided full-thickness necrosis is absent and the muscular layer can just maintain its structural integrity. ETGBD, the only drainage modality that does not involve direct gallbladder puncture, may serve as an alternative in severe cholecystitis cases where other approaches, including surgery, are contraindicated.</p><p>However, ETGBD presents significant technical challenges. A recent meta-analysis has reported a pooled technical success rate of 83% (95% CI: 80.1–85.5; <i>I</i><sup>2</sup> = 29) [<span>3</span>]. In comparison, percutaneous drainage and EUS-guided drainage achieve success rates of 99% and 95%, respectively. Consequently, ETGBD cannot currently replace these more established procedures. Moreover, even if technically successful, ETGBD carries a risk of post-procedural pancreatitis.</p><p>In addition, its clinical success rate is modest. Mohan et al. have reported a pooled clinical success rate of 88% for ETGBD, compared to 89% for percutaneous drainage and 97% for EUS-guided drainage [<span>3</span>]. ETGBD inherits the limitations of both alternatives: irrigation cannot be performed through an external tube (like EUS-guided drainage), and it uses a relatively narrow catheter (like percutaneous drainage) [<span>4</span>].</p><p>Therefore, ETGBD may be most appropriate for patients with contraindi
坏疽性胆囊炎(GC)是一种危及生命的急性胆囊炎,其特征是胆囊壁全层坏死。其发病机制包括缺血和血管损伤,通常由长期炎症、囊性动脉阻塞或腔内压升高引起。组织学上,GC表现为跨壁坏死、出血和密集的中性粒细胞浸润。胆囊壁可表现为完全的粘膜坏死,血管血栓形成,在某些情况下,还可出现壁内脓肿。这些特征强调了疾病的严重性及其并发症的高风险,包括穿孔和腹膜炎。急诊胆囊切除术仍然是胃癌的标准治疗方法。这在很大程度上是因为通过胆囊穿刺减压(传统上通过经皮途径,最近通过超声创建的途径)与穿孔的高风险相关。与弹性肌肉组织不同,坏疽胆囊脆弱的壁缺乏结构完整性来固定导管。脆弱的囊壁在腔内高压下几乎无法维持其形状,一旦被刺破,囊壁可能会不可挽回地坍塌。相比之下,内镜下经乳头胆囊引流(ETGBD)提供了一种非穿刺的选择,可以促进选定的GC病例的恢复。如果坏疽性改变几乎不可逆,非穿刺引流可支持保守治疗。即使发生了不可逆的粘膜损伤,只要没有全层坏死,肌肉层能保持其结构的完整性,胆囊在炎症消退后仍能保持其结构。ETGBD是唯一一种不涉及直接胆囊穿刺的引流方式,可作为严重胆囊炎病例的一种替代方法,其中包括手术。然而,ETGBD提出了重大的技术挑战。最近的一项荟萃分析报告了技术成功率为83% (95% CI: 80.1-85.5; I2 = 29)。经皮引流和eus引导引流的成功率分别为99%和95%。因此,ETGBD目前不能取代这些更成熟的程序。此外,即使技术上成功,ETGBD也有术后胰腺炎的风险。此外,其临床成功率不高。Mohan等人报道了ETGBD的临床总成功率为88%,而经皮引流为89%,eus引导引流为97%。ETGBD继承了这两种替代方法的局限性:不能通过外置管(如eus引导引流)进行灌洗,并且使用相对狭窄的导管(如经皮引流)[4]。因此,ETGBD可能最适合于对所有其他引流方式有禁忌症的患者,例如那些有严重凝血障碍或大量腹水的患者。此外,对于接受ERCP取出胆管结石的患者,也可考虑采用该方法,为同时进行胆囊引流提供机会。对于晚期恶性肿瘤患者,使用ETGBD可能有助于避免手术和永久性外引流的需要。此外,GC本身可能成为ETGBD的新适应症。在Nakahara等人的一项回顾性研究中,比较了坏疽性和非坏疽性胆囊炎[5]患者的ETGBD结果。GC的定义是通过对比增强的CT表现,如缺乏壁增强、壁不规则或无壁、腔内膜、囊周脓肿、壁或腔内气体。技术成功率分别为86%对92%,临床成功率为79%对92%,不良事件发生率为28%对16%。虽然坏疽组的预后较差,但超过三分之二的患者(86% × 79% = 67.9%)取得了临床成功。考虑到胃癌通常需要紧急手术,这个结果在高度复杂、高风险的患者中是可以接受的。如果在未来的研究中确定预测技术和临床成功的因素,可能会有所帮助。此外,应明确临床或影像学特征确定的禁忌症。必须解决技术挑战,使ETGBD更广泛地适用。现有的报告主要来自由具有丰富ETGBD经验的专家组成的高容量中心[6-8]。一般情况下,结果可能不太理想。技术上的改进必须不仅包括提高操作人员的熟练程度,还包括进入囊管的标准化技术,开发用于导航扭曲解剖结构的导丝,以及优化支架的顺利部署。此外,ETGBD与经皮引流的临床对比数据缺乏,迫切需要。 必须仔细评估ETGBD的程序负担,包括更长的持续时间、更高的镇静剂要求和失败后恶化的风险。应对不良事件的策略,特别是胰腺炎和胆囊管穿孔,以及处理失败的ETGBD,包括随后的干预措施,应该明确概述[9,10]。一旦这些局限性得到充分理解和解决,ETGBD的临床适应症就可以更精确地描述。尽管存在挑战,但ETGBD在某些情况下可能成为一种可行的选择,特别是在凝血功能障碍、腹水、并发胆管结石或坏疽性胆囊炎等患者不适合手术的情况下。作者声明无利益冲突。这篇文章链接到Nakahara等人的论文。要查看本文,请访问https://doi.org/10.1111/den.15050
{"title":"Endoscopic Transpapillary Gallbladder Drainage for Gangrenous Cholecystitis: A Minimally Invasive Approach Under Scrutiny","authors":"Yoshihide Kanno","doi":"10.1111/den.70004","DOIUrl":"10.1111/den.70004","url":null,"abstract":"&lt;p&gt;Gangrenous cholecystitis (GC) is a life-threatening form of acute cholecystitis characterized by full-thickness necrosis of the gallbladder wall. The pathogenesis involves ischemia and vascular compromise, typically resulting from prolonged inflammation, cystic artery obstruction, or elevated intraluminal pressure [&lt;span&gt;1&lt;/span&gt;]. Histologically, GC is marked by transmural necrosis, hemorrhaging, and dense neutrophilic infiltration. The gallbladder wall may exhibit complete mucosal necrosis, vascular thrombosis, and, in some cases, intramural abscesses. These features underscore the severity of the disease and its high risk of complications, including perforation and peritonitis.&lt;/p&gt;&lt;p&gt;Emergency cholecystectomy remains the standard treatment for GC [&lt;span&gt;2&lt;/span&gt;]. This is largely because decompression via gallbladder puncture (traditionally through a percutaneous route and more recently via endosonographically created routes) has been associated with a high risk of perforation. The friable wall of a gangrenous gallbladder lacks the structural integrity to secure a catheter, unlike resilient muscular tissue. Once punctured, the fragile cystic wall, which barely maintains its shape under high intraluminal pressure, may collapse irreparably.&lt;/p&gt;&lt;p&gt;In contrast, endoscopic transpapillary gallbladder drainage (ETGBD) offers a non-puncture alternative that could facilitate recovery in selected GC cases. If the gangrenous changes are barely reversible, non-puncture drainage may support conservative healing. Even when irreversible mucosal damage has occurred, the gallbladder may retain its structure following the resolution of inflammation, provided full-thickness necrosis is absent and the muscular layer can just maintain its structural integrity. ETGBD, the only drainage modality that does not involve direct gallbladder puncture, may serve as an alternative in severe cholecystitis cases where other approaches, including surgery, are contraindicated.&lt;/p&gt;&lt;p&gt;However, ETGBD presents significant technical challenges. A recent meta-analysis has reported a pooled technical success rate of 83% (95% CI: 80.1–85.5; &lt;i&gt;I&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 29) [&lt;span&gt;3&lt;/span&gt;]. In comparison, percutaneous drainage and EUS-guided drainage achieve success rates of 99% and 95%, respectively. Consequently, ETGBD cannot currently replace these more established procedures. Moreover, even if technically successful, ETGBD carries a risk of post-procedural pancreatitis.&lt;/p&gt;&lt;p&gt;In addition, its clinical success rate is modest. Mohan et al. have reported a pooled clinical success rate of 88% for ETGBD, compared to 89% for percutaneous drainage and 97% for EUS-guided drainage [&lt;span&gt;3&lt;/span&gt;]. ETGBD inherits the limitations of both alternatives: irrigation cannot be performed through an external tube (like EUS-guided drainage), and it uses a relatively narrow catheter (like percutaneous drainage) [&lt;span&gt;4&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Therefore, ETGBD may be most appropriate for patients with contraindi","PeriodicalId":159,"journal":{"name":"Digestive Endoscopy","volume":"37 11","pages":"1231-1232"},"PeriodicalIF":4.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/den.70004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144709946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Greetings From the New Editor-in-Chief of Digestive Endoscopy 《消化内窥镜》杂志新任总编辑的问候。
IF 4.7 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-07-25 DOI: 10.1111/den.15088
Masayuki Kitano
{"title":"Greetings From the New Editor-in-Chief of Digestive Endoscopy","authors":"Masayuki Kitano","doi":"10.1111/den.15088","DOIUrl":"10.1111/den.15088","url":null,"abstract":"","PeriodicalId":159,"journal":{"name":"Digestive Endoscopy","volume":"37 11","pages":"1229-1230"},"PeriodicalIF":4.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144709947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding the Role of Computer-Aided Diagnosis in Colonoscopy 了解计算机辅助诊断在结肠镜检查中的作用。
IF 4.7 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-07-25 DOI: 10.1111/den.70007
Natalie Halvorsen, Yuichi Mori
<p>When confronted with computer-aided diagnosis (CADx) suggesting the neoplastic potential of a polyp, should the clinician trust the CADx? A common assumption is that inexperienced clinicians might benefit from trusting CADx, and that experienced clinicians might not because of already high competence in optical diagnosis [<span>1</span>].</p><p>In this issue of <i>Digestive Endoscopy</i>, Shinozaki et al. [<span>2</span>] compared the diagnostic performance of CADx against both inexperienced and experienced endoscopists by performing a systematic review and meta-analysis of 21 studies with 5477 colorectal polyps. The study showed that CADx did not outperform the endoscopists, regardless of their experience level. The pooled sensitivities and specificities were nearly identical between CADx with 0.87 (95% confidence interval [CI]: 0.82–0.91) and 0.85 (95% CI: 0.78–0.90), respectively, and 0.88 (95% CI: 0.83–0.91) and 0.87 (95% CI: 0.82–0.92), respectively, for the experienced endoscopists. In another comparison, the pooled sensitivities and specificities were 0.88 (95% CI: 0.82–0.92) and 0.84 (95% CI: 0.78–0.88), respectively, for CADx, and 0.85 (95% CI: 0.78–0.90) and 0.77 (95% CI: 0.70–0.83), respectively, for inexperienced endoscopists. Summary Receiver Operating Characteristic (SROC) curves with visual inspection were used to estimate heterogeneity, which indicated greater variability in the inexperienced endoscopists. The area under the curve (AUC) for CADx was significantly greater compared to inexperienced endoscopists; however, the overlapping intervals and modest effect size caution against claiming true superiority.</p><p>The relevance of this research lies in its contribution to the framework used to develop clinical guidelines. Subgroup or stratified reviews, such as this, are essential to prevent post hoc speculation on subgroup effects and to increase the certainty of evidence supporting recommendations. By analyzing larger subgroups, we allow for variations in treatment effects to be exposed, thus increasing the precision of the evidence. This approach helps prevent potential biases that could arise from interpreting results based solely on the whole group (endoscopists). The GRADE framework underscores that the strength of any guideline is contingent on the quality of the evidence itself, rather than the authority of experts or researchers involved [<span>3</span>]. By minimizing biases and preventing overenthusiasm combined with underpowered results, we can make informed decisions regarding resource allocation in healthcare. In this context, the findings indicate that the separate use of CADx does not enhance current clinical care and may not warrant further investment. This insight is critical for directing healthcare spending toward interventions that yield greater benefit for the patient.</p><p>We must continue to pursue targeted investigation into the clinical relevance of interventions such as CADx assisting endoscopists [
当面对计算机辅助诊断(CADx)提示息肉的肿瘤潜力时,临床医生应该相信CADx吗?一个普遍的假设是,没有经验的临床医生可能会从信任CADx中受益,而有经验的临床医生可能不会,因为他们在光学诊断方面的能力已经很高了。在本期的《消化道内窥镜》杂志上,Shinozaki等人对21项5477例结直肠息肉的研究进行了系统回顾和荟萃分析,比较了CADx对经验不足和经验丰富的内窥镜医师的诊断效果。研究表明,无论内窥镜医生的经验水平如何,CADx的表现都没有超过他们。CADx的总敏感性和特异性几乎相同,分别为0.87(95%可信区间[CI]: 0.82-0.91)和0.85 (95% CI: 0.78-0.90),经验丰富的内镜医师的总敏感性和特异性分别为0.88 (95% CI: 0.83-0.91)和0.87 (95% CI: 0.82-0.92)。在另一项比较中,CADx的总敏感性和特异性分别为0.88 (95% CI: 0.82-0.92)和0.84 (95% CI: 0.78-0.88),经验不足的内窥镜医师的总敏感性和特异性分别为0.85 (95% CI: 0.78-0.90)和0.77 (95% CI: 0.70-0.83)。采用目视检查的总体受试者工作特征(SROC)曲线来估计异质性,结果表明经验不足的内窥镜医师的差异更大。与经验不足的内窥镜医师相比,CADx的曲线下面积(AUC)明显更大;然而,重叠的间隔和适度的效应大小提醒我们不要声称真正的优势。这项研究的相关性在于它对用于制定临床指南的框架的贡献。诸如此类的亚组或分层评价对于防止对亚组效应的事后猜测和增加支持建议的证据的确定性至关重要。通过分析更大的亚组,我们允许暴露治疗效果的变化,从而提高证据的准确性。这种方法有助于防止由于仅仅基于整个群体(内窥镜医师)来解释结果而产生的潜在偏差。GRADE框架强调,任何指南的效力取决于证据本身的质量,而不是相关专家或研究人员的权威。通过最大限度地减少偏见,防止过度热情与动力不足的结果相结合,我们可以在医疗保健资源分配方面做出明智的决定。在这种情况下,研究结果表明单独使用CADx并不能提高当前的临床护理水平,也不值得进一步投资。这种洞察力对于引导医疗保健支出用于对患者产生更大益处的干预措施至关重要。我们必须继续有针对性地研究诸如辅助内窥镜医师的CADx等干预措施的临床相关性。此外,对CADx工具的评价在未来可能会发生变化,因为这不仅仅取决于该工具的敏感性和特异性。CADx的重点可能是增加对息肉诊断的信心,从而促进适当的息肉处理策略,如留在原位、切除并丢弃和丢弃-生命[5,6]。患者对人工智能的乐观态度也可能影响到他们寻求治疗的地点,这凸显了透明的医患沟通的重要性。我们还应该考虑到,人工智能和人类之间的交流可能会因为未知的影响因素(混杂因素)而发生偏差。其中一个例子是“锚定”偏见,当临床医生无视人工智能时,就会发生这种情况,因为人工智能的建议在临床医生自己的诊断之后几秒钟就会出现。这项研究为应用循证医学建立良好实践和合理分配资金和资源提供了重要见解。该研究还强调了进一步研究的必要性,以便与内镜医师一起正确评估CADx的临床应用。构思主题并起草初稿。Y.M.提供了重要的修订和编辑指导。两位作者都认可了最终版本。-奥林巴斯公司(咨询、演讲酬金、设备外借);Cybernet System Corp.(授权费)。链接文章“计算机辅助诊断结肠直肠息肉与内镜医师的比较:系统回顾和荟萃分析”的社论评论https://doi.org/10.1111/den.15047。
{"title":"Understanding the Role of Computer-Aided Diagnosis in Colonoscopy","authors":"Natalie Halvorsen,&nbsp;Yuichi Mori","doi":"10.1111/den.70007","DOIUrl":"10.1111/den.70007","url":null,"abstract":"&lt;p&gt;When confronted with computer-aided diagnosis (CADx) suggesting the neoplastic potential of a polyp, should the clinician trust the CADx? A common assumption is that inexperienced clinicians might benefit from trusting CADx, and that experienced clinicians might not because of already high competence in optical diagnosis [&lt;span&gt;1&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;In this issue of &lt;i&gt;Digestive Endoscopy&lt;/i&gt;, Shinozaki et al. [&lt;span&gt;2&lt;/span&gt;] compared the diagnostic performance of CADx against both inexperienced and experienced endoscopists by performing a systematic review and meta-analysis of 21 studies with 5477 colorectal polyps. The study showed that CADx did not outperform the endoscopists, regardless of their experience level. The pooled sensitivities and specificities were nearly identical between CADx with 0.87 (95% confidence interval [CI]: 0.82–0.91) and 0.85 (95% CI: 0.78–0.90), respectively, and 0.88 (95% CI: 0.83–0.91) and 0.87 (95% CI: 0.82–0.92), respectively, for the experienced endoscopists. In another comparison, the pooled sensitivities and specificities were 0.88 (95% CI: 0.82–0.92) and 0.84 (95% CI: 0.78–0.88), respectively, for CADx, and 0.85 (95% CI: 0.78–0.90) and 0.77 (95% CI: 0.70–0.83), respectively, for inexperienced endoscopists. Summary Receiver Operating Characteristic (SROC) curves with visual inspection were used to estimate heterogeneity, which indicated greater variability in the inexperienced endoscopists. The area under the curve (AUC) for CADx was significantly greater compared to inexperienced endoscopists; however, the overlapping intervals and modest effect size caution against claiming true superiority.&lt;/p&gt;&lt;p&gt;The relevance of this research lies in its contribution to the framework used to develop clinical guidelines. Subgroup or stratified reviews, such as this, are essential to prevent post hoc speculation on subgroup effects and to increase the certainty of evidence supporting recommendations. By analyzing larger subgroups, we allow for variations in treatment effects to be exposed, thus increasing the precision of the evidence. This approach helps prevent potential biases that could arise from interpreting results based solely on the whole group (endoscopists). The GRADE framework underscores that the strength of any guideline is contingent on the quality of the evidence itself, rather than the authority of experts or researchers involved [&lt;span&gt;3&lt;/span&gt;]. By minimizing biases and preventing overenthusiasm combined with underpowered results, we can make informed decisions regarding resource allocation in healthcare. In this context, the findings indicate that the separate use of CADx does not enhance current clinical care and may not warrant further investment. This insight is critical for directing healthcare spending toward interventions that yield greater benefit for the patient.&lt;/p&gt;&lt;p&gt;We must continue to pursue targeted investigation into the clinical relevance of interventions such as CADx assisting endoscopists [","PeriodicalId":159,"journal":{"name":"Digestive Endoscopy","volume":"37 11","pages":"1227-1228"},"PeriodicalIF":4.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/den.70007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144709948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Statuses of Colonoscopy and Colorectal Cancer According to Big National Disasters Such as COVID-19 and Earthquake 新型冠状病毒病、地震等重大国家灾害对结肠镜检查和结直肠癌的影响
IF 4.7 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-07-17 DOI: 10.1111/den.15084
Naohisa Yoshida, Ayako Maeda-Minami, Michihiro Mutoh, Naoto Iwai, Reo Kobayashi, Ken Inoue, Osamu Dohi, Yoshito Itoh, Ryohei Hirose, Yasunari Mano, Lucas Cardoso, Hideki Ishikawa

Objectives

Sudden decrease of colonoscopy (CS) numbers can be related to the status of colorectal cancer (CRC). This study aimed to evaluate the statuses of CS and CRC according to big national disasters such as the Great East Japan Earthquake in 2011 and the COVID-19 epidemic in 2020.

Methods

We retrospectively used the JMDC database of commercially anonymized health insurance claims data including 4,601,921 patients ≥ 50 years old from January 2010 to December 2022 (without health checkups of CS and esophagogastroduodenoscopy [EGD]). The main outcome was a yearly analysis for 2010–2022 about (1) rate of CS, (2) rate of CRC and rate of CRC per CS compared to those of EGD and gastric cancer (GC), and (3) rate of surgery for CRC. Additionally, a monthly analysis for those rates was performed to examine the detailed effect of the earthquake and COVID-19 infection.

Results

The rates of CS and EGD in 2010/2011/2012 were 3.10%/3.41%/3.42% and 6.94%/6.96%/7.00% and those in 2019/2020/2021 were 5.20%/4.74%/5.37% and 7.47%/6.42%/6.84%, respectively. The rates of CS and EGD decreased not in 2011 (The earthquake) but in 2020 (COVID-19). The rates of CRC and GC in 2019/2020/2021 were 0.199%/0.175%/0.195% and 0.110%/0.096%/0.099%, and both showed a decrease in 2020. Monthly analysis showed that the rate of CRC per CS had an increase in April and May in 2020 compared to that in March of 2020. The rate of surgery for CRC in 2019/2020/2021 was 0.087%/0.079%/0.087% with a deficiency in 2020.

Conclusions

The rates of CS and CRC decreased in 2020 due to COVID-19.

目的:结肠镜检查(CS)次数突然减少可能与结直肠癌(CRC)的状态有关。本研究旨在结合2011年东日本大地震和2020年新冠肺炎疫情等重大国家灾害,评估CS和CRC的现状。方法:我们回顾性使用JMDC数据库的商业匿名医疗保险索赔数据,包括2010年1月至2022年12月期间4601,921名年龄≥50岁的患者(未进行CS和食管胃十二指肠镜检查[EGD])。主要结果是2010-2022年的年度分析(1)CS发病率,(2)结直肠癌发病率和与EGD和胃癌(GC)相比的每CS结直肠癌发病率,以及(3)结直肠癌手术率。此外,还对这些比率进行了月度分析,以检查地震和COVID-19感染的详细影响。结果:2010/2011/2012年CS和EGD检出率分别为3.10%/3.41%/3.42%和6.94%/6.96%/7.00%,2019/2020/2021年CS和EGD检出率分别为5.20%/4.74%/5.37%和7.47%/6.42%/6.84%。CS和EGD的发生率不是在2011年(地震)下降,而是在2020年(COVID-19)下降。2019/2020/2021年CRC和GC率分别为0.199%/0.175%/0.195%和0.110%/0.096%/0.099%,2020年均呈下降趋势。月度分析显示,2020年4月和5月每CS结直肠癌发生率较2020年3月有所上升。2019/2020/2021年结直肠癌手术率为0.087%/0.079%/0.087%,2020年有所欠缺。结论:2020年受COVID-19影响,CS和CRC的发生率有所下降。
{"title":"The Statuses of Colonoscopy and Colorectal Cancer According to Big National Disasters Such as COVID-19 and Earthquake","authors":"Naohisa Yoshida,&nbsp;Ayako Maeda-Minami,&nbsp;Michihiro Mutoh,&nbsp;Naoto Iwai,&nbsp;Reo Kobayashi,&nbsp;Ken Inoue,&nbsp;Osamu Dohi,&nbsp;Yoshito Itoh,&nbsp;Ryohei Hirose,&nbsp;Yasunari Mano,&nbsp;Lucas Cardoso,&nbsp;Hideki Ishikawa","doi":"10.1111/den.15084","DOIUrl":"10.1111/den.15084","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Sudden decrease of colonoscopy (CS) numbers can be related to the status of colorectal cancer (CRC). This study aimed to evaluate the statuses of CS and CRC according to big national disasters such as the Great East Japan Earthquake in 2011 and the COVID-19 epidemic in 2020.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively used the JMDC database of commercially anonymized health insurance claims data including 4,601,921 patients ≥ 50 years old from January 2010 to December 2022 (without health checkups of CS and esophagogastroduodenoscopy [EGD]). The main outcome was a yearly analysis for 2010–2022 about (1) rate of CS, (2) rate of CRC and rate of CRC per CS compared to those of EGD and gastric cancer (GC), and (3) rate of surgery for CRC. Additionally, a monthly analysis for those rates was performed to examine the detailed effect of the earthquake and COVID-19 infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The rates of CS and EGD in 2010/2011/2012 were 3.10%/3.41%/3.42% and 6.94%/6.96%/7.00% and those in 2019/2020/2021 were 5.20%/4.74%/5.37% and 7.47%/6.42%/6.84%, respectively. The rates of CS and EGD decreased not in 2011 (The earthquake) but in 2020 (COVID-19). The rates of CRC and GC in 2019/2020/2021 were 0.199%/0.175%/0.195% and 0.110%/0.096%/0.099%, and both showed a decrease in 2020. Monthly analysis showed that the rate of CRC per CS had an increase in April and May in 2020 compared to that in March of 2020. The rate of surgery for CRC in 2019/2020/2021 was 0.087%/0.079%/0.087% with a deficiency in 2020.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The rates of CS and CRC decreased in 2020 due to COVID-19.</p>\u0000 </section>\u0000 </div>","PeriodicalId":159,"journal":{"name":"Digestive Endoscopy","volume":"37 11","pages":"1190-1197"},"PeriodicalIF":4.7,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Clinical Success of Endoscopic Ultrasound-Guided Gastroenterostomy in Benign Gastric Outlet Obstruction 超声内镜引导下胃造口术治疗良性胃出口梗阻的长期临床成功。
IF 4.7 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-07-17 DOI: 10.1111/den.15087
Antonio Martinez-Ortega, F. Javier García-Alonso, Natalia Marcos Carrasco, Amaia Arrubla Gamboa, Lucía Guilabert, Carlos Abril García, Félix Téllez-Avila, José Carlos Subtil Íñigo, Belén Martínez-Moreno, Marina Cobreros del Caz, Juan J. Vila, Vicente Sanchiz Soler, José R. Aparicio Tormo, Alejandro Repiso Ortega, José Miguel Esteban, Antonio Velasco-Guardado, Ferrán Gónzalez-Huix, Carlos de la Serna Higuera, Manuel Perez-Miranda

Background and Aims

Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) is an established treatment for malignant gastric outlet obstruction (GOO). Data on EUS-GE for benign GOO (bGOO) are limited. This study aimed to evaluate long-term clinical outcomes of EUS-GE in bGOO.

Methods

Retrospective study on consecutive patients who underwent EUS-GE for bGOO using lumen apposing metal stents (LAMS) at 9 Spanish centers. The primary outcome was the ability to regain and maintain oral feeding. Secondary outcomes included technical success, immediate clinical success, LAMS dysfunction, and adverse event rates.

Results

Sixty-two patients (75.8% male) with a median age of 65 years (56.9–74) were included. Most cases of bGOO were related to chronic (35.5%) or acute (24.2%) pancreatitis. Technical success was achieved in 61 (98.4%), and immediate clinical success in 57 (91.9%) patients. Among patients reaching immediate clinical success, the median LAMS indwell time was 505 (201–848) days. LAMS dysfunction developed in 7 (12.3%) patients after a median of 1200 (IQR: 94–1568) days. Oral feeding at 24 months was maintained in 85.3% patients overall and in 93.6% patients among those with immediate clinical success. Seven adverse events, including a fatal aspiration pneumonia and a fatal delayed bleeding, occurred in 6 (9.7%) patients.

Conclusions

EUS-GE has a high immediate clinical success rate in patients with bGOO and a low risk of stent dysfunction.

Trial Registration

Promotor center identification number: PI-24-448-H

背景与目的:超声内镜引导下的胃肠造口术(EUS-GE)是治疗恶性胃出口梗阻(GOO)的常用方法。EUS-GE诊断良性粘胶瘤(bGOO)的数据有限。本研究旨在评估EUS-GE治疗bGOO的长期临床结果。方法:回顾性研究西班牙9个中心连续使用腔内金属支架(LAMS)行EUS-GE治疗bGOO的患者。主要结果是恢复和维持口服喂养的能力。次要结局包括技术成功、即时临床成功、LAMS功能障碍和不良事件发生率。结果:纳入62例患者,男性75.8%,中位年龄65岁(56.9-74岁)。大多数bGOO病例与慢性(35.5%)或急性(24.2%)胰腺炎有关。技术成功61例(98.4%),即刻临床成功57例(91.9%)。在立即获得临床成功的患者中,LAMS留置时间中位数为505(201-848)天。7例(12.3%)患者在中位1200 (IQR: 94-1568)天后出现LAMS功能障碍。总体而言,85.3%的患者在24个月时维持口服喂养,在立即取得临床成功的患者中,这一比例为93.6%。6例(9.7%)患者发生了7个不良事件,包括致命性吸入性肺炎和致命性延迟性出血。结论:EUS-GE治疗bGOO患者临床即刻成功率高,支架功能障碍风险低。试验注册:启动子中心识别号:PI-24-448-H。
{"title":"Long-Term Clinical Success of Endoscopic Ultrasound-Guided Gastroenterostomy in Benign Gastric Outlet Obstruction","authors":"Antonio Martinez-Ortega,&nbsp;F. Javier García-Alonso,&nbsp;Natalia Marcos Carrasco,&nbsp;Amaia Arrubla Gamboa,&nbsp;Lucía Guilabert,&nbsp;Carlos Abril García,&nbsp;Félix Téllez-Avila,&nbsp;José Carlos Subtil Íñigo,&nbsp;Belén Martínez-Moreno,&nbsp;Marina Cobreros del Caz,&nbsp;Juan J. Vila,&nbsp;Vicente Sanchiz Soler,&nbsp;José R. Aparicio Tormo,&nbsp;Alejandro Repiso Ortega,&nbsp;José Miguel Esteban,&nbsp;Antonio Velasco-Guardado,&nbsp;Ferrán Gónzalez-Huix,&nbsp;Carlos de la Serna Higuera,&nbsp;Manuel Perez-Miranda","doi":"10.1111/den.15087","DOIUrl":"10.1111/den.15087","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) is an established treatment for malignant gastric outlet obstruction (GOO). Data on EUS-GE for benign GOO (bGOO) are limited. This study aimed to evaluate long-term clinical outcomes of EUS-GE in bGOO.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Retrospective study on consecutive patients who underwent EUS-GE for bGOO using lumen apposing metal stents (LAMS) at 9 Spanish centers. The primary outcome was the ability to regain and maintain oral feeding. Secondary outcomes included technical success, immediate clinical success, LAMS dysfunction, and adverse event rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Sixty-two patients (75.8% male) with a median age of 65 years (56.9–74) were included. Most cases of bGOO were related to chronic (35.5%) or acute (24.2%) pancreatitis. Technical success was achieved in 61 (98.4%), and immediate clinical success in 57 (91.9%) patients. Among patients reaching immediate clinical success, the median LAMS indwell time was 505 (201–848) days. LAMS dysfunction developed in 7 (12.3%) patients after a median of 1200 (IQR: 94–1568) days. Oral feeding at 24 months was maintained in 85.3% patients overall and in 93.6% patients among those with immediate clinical success. Seven adverse events, including a fatal aspiration pneumonia and a fatal delayed bleeding, occurred in 6 (9.7%) patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>EUS-GE has a high immediate clinical success rate in patients with bGOO and a low risk of stent dysfunction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>Promotor center identification number: PI-24-448-H</p>\u0000 </section>\u0000 </div>","PeriodicalId":159,"journal":{"name":"Digestive Endoscopy","volume":"37 11","pages":"1198-1206"},"PeriodicalIF":4.7,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Awareness Survey on Green Endoscopy for Endoscopists in Japan 日本内镜医师对绿色内镜的认知调查。
IF 4.7 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-07-16 DOI: 10.1111/den.70000
Shunsuke Yamamoto, Hiroyasu Iishi, Mathieu Pioche
{"title":"Awareness Survey on Green Endoscopy for Endoscopists in Japan","authors":"Shunsuke Yamamoto,&nbsp;Hiroyasu Iishi,&nbsp;Mathieu Pioche","doi":"10.1111/den.70000","DOIUrl":"10.1111/den.70000","url":null,"abstract":"","PeriodicalId":159,"journal":{"name":"Digestive Endoscopy","volume":"37 11","pages":"1246-1247"},"PeriodicalIF":4.7,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
WEO Newsletter: The Impact of Artificial Intelligence on Management of Inflammatory Bowel Disease: An Expert Commentary WEO通讯:人工智能对炎症性肠病管理的影响:专家评论
IF 5 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-07-10 DOI: 10.1111/den.15072
<p>By Nayantara Coelho-Prabhu, MD FACG AGAF FASGE, Mayo Clinic Rochester</p><p>The complexity of IBD, including both Crohn's disease (CD) and ulcerative colitis (UC), lies in its heterogeneity in presentation, unpredictable disease course, and varying responses to therapy. Current approaches rely on a combination of clinical indices, imaging, endoscopy, histology, and biomarkers—many of which are subjective and variably interpreted. This subjectivity results in difficulties with establishing standards of care, and often is the root cause of complications. Also, there is an increasing focus on achieving healing in IBD across all aspects of the disease including clinical, radiologic, endoscopic and histologic (STRIDE-II). To achieve this, we must establish standardization across these targets. These challenges present a fertile ground for AI applications aimed at improving accuracy, efficiency, and personalization in IBD management.</p><p>Endoscopic assessment remains central to IBD diagnosis and monitoring. However, the qualitative nature of inflammation scoring and interobserver variability in all scoring systems such as the Mayo Endoscopic Score or SES-CD has long plagued clinical and research settings. This has been the impetus to develop automated scoring systems that aim to standardize these scores. The first iteration of these models used still images to train convoluted neural networks (CNNs) and then reported on their successful scoring of test data still images. These systems utilized expert scoring as the gold standard, and they were found to have excellent performance in distinguishing Mayo 0-1 from Mayo 2-3 scores, similar to human experts. The next step was that CNNs were trained to read video segments, obtained from pharmaceutical randomized trials that had captured video segments, scored by central readers. Because the earlier systems were compared to human gold standard, which has low interoperator agreement, the next step in this evolution was to consider disease outcome as a measure of validity. Again, clinical trial videos were used and the CNNs were trained to report a cumulative disease score that was correlated with outcomes with more meaningful results. The goal is to be able to predict responders from non-responders. AI can detect subtle visual features on endoscopy, which can be harnessed to make histologic inference without the need for biopsy. Such predictive CNNs have been developed using white light images as well as enhanced imaging techniques including endocytoscopy, narrow band imaging (vascular patterns) and I-scan. These can predict relapse rates based on real-time endoscope imaging with great accuracy. In capsule enteroscopy, AI has been developed to accurately identify and quantify small bowel ulcerations, and significantly reduce capsule reading time, for both trainees and experts. These recent AI-driven computer vision tools have demonstrated the ability to automatically segment mucosal features, detect ulcera
包括克罗恩病(CD)和溃疡性结肠炎(UC)在内的IBD的复杂性在于其表现的异质性、不可预测的病程和对治疗的不同反应。目前的方法依赖于临床指标、影像学、内窥镜检查、组织学和生物标志物的组合,其中许多是主观的,解释也不尽相同。这种主观性导致了建立护理标准的困难,并且往往是并发症的根本原因。此外,人们越来越关注在IBD的各个方面实现治愈,包括临床、放射学、内窥镜和组织学(STRIDE-II)。为了实现这一目标,我们必须在这些目标之间建立标准化。这些挑战为旨在提高IBD管理的准确性、效率和个性化的人工智能应用提供了肥沃的土壤。内镜评估仍然是IBD诊断和监测的核心。然而,在Mayo内镜评分或SES-CD等所有评分系统中,炎症评分的定性性质和观察者间的可变性长期困扰着临床和研究机构。这推动了旨在标准化这些分数的自动评分系统的开发。这些模型的第一次迭代使用静态图像来训练卷积神经网络(cnn),然后报告它们对测试数据静态图像的成功评分。这些系统以专家评分为金标准,在区分Mayo 0-1和Mayo 2-3分方面表现出色,与人类专家相似。下一步是cnn被训练来阅读视频片段,这些视频片段是从抓取视频片段的药物随机试验中获得的,由中央阅读器评分。由于早期的系统与人类黄金标准相比,操作者之间的一致性较低,因此这种进化的下一步是将疾病结果作为有效性的衡量标准。再一次,临床试验视频被使用,cnn被训练来报告累积疾病评分,该评分与结果更有意义的结果相关。目标是能够从无反应者中预测反应者。人工智能可以在内窥镜上检测到细微的视觉特征,从而可以在不需要活检的情况下进行组织学推断。这种预测cnn已经开发使用白光图像以及增强的成像技术,包括内吞镜,窄带成像(血管模式)和i扫描。这些可以基于实时内窥镜成像非常准确地预测复发率。在胶囊肠镜检查中,人工智能已经被开发出来,可以准确地识别和量化小肠溃疡,并显着减少胶囊阅读时间,无论是对学员还是专家。这些最近的人工智能驱动的计算机视觉工具已经证明了自动分割粘膜特征、检测溃疡和量化炎症的能力,并且具有高重复性。深度学习模型为实时、标准化的疾病活动评分和预测护理点的未来结果提供了潜力。组织学缓解正在成为IBD的一个关键治疗目标,但其评估是劳动密集型的,容易出现主观性。在数字病理切片上训练的人工智能算法已经开始自动量化中性粒细胞、隐窝扭曲和上皮损伤,从而实现了Nancy或roberts组织病理学指数等指标的标准化应用。一种通过指数活检预测克罗恩病未来表型表现的算法也显示了人工智能在IBD组织学中的潜力。整个幻灯片的数字化和大数据计算能力的快速扩展是人工智能在该领域快速发展的一些因素。这些工具不仅减轻了病理学家的负担,而且提高了检测可能复发的亚临床炎症的敏感性,从而指导强化治疗。这种算法在全球范围内应用的潜力令人兴奋,尤其是在新兴国家。然而,在算法开发过程中,对代表性数据的包含保持警惕以避免偏差是至关重要的。长期结肠炎患者患结直肠发育不良和癌症的风险增加。有针对性的活检的监视结肠镜检查是标准的,但扁平和细微的病变往往未被发现。人工智能辅助内窥镜检查,特别是计算机辅助检测(CADe)系统,已被证明可以改善非ibd筛查和监测结肠镜检查中的腺瘤检测。然而,在多项研究中,将这些针对非IBD患者开发的CADe系统应用于IBD监测结肠镜检查时,它们的表现并不好。特别是扁平病变和活动性炎症区病变的漏报率较高。 因此,利用IBD监测结肠镜检查的发育不良病变图像对系统进行了重新训练,结果显示IBD的发育不良检测有明显改善。因此,从业人员在直接将这些可用的CADe系统用于IBD监测时应谨慎,因为到目前为止,还没有商业上可用的系统经过专门培训或被批准用于IBD监测。在未来,可以开发整合内镜和组织学特征的系统,以分层不典型增生的风险,潜在的个性化监测间隔和活检策略。横断面成像在评估跨壁和外壁疾病,特别是克罗恩病中起着至关重要的作用。放射组学是一种从放射图像中提取高维特征的人工智能,在表征肠壁厚度、血管分布和纤维化方面显示出了希望。自动肠分割的改进有助于使用CT和MR肠片自动提取克罗恩病的活动测量,这反过来又用于开发标准化报告的算法。当与临床数据相结合时,人工智能模型可以区分炎症性和纤维化性狭窄,这对于选择医疗还是手术治疗至关重要。深度学习工具还有助于识别瘘和脓肿等并发症,提高了准确性,减少了解释时间。人工智能在医学上的应用,如组织学,在提供高质量医疗民主化方面具有广泛的影响,特别是在世界上缺乏资源和专业知识的地区。人工智能在IBD中的一个改变实践的应用在于NLP,它允许从电子健康记录(EHRs)中的结构化和非结构化临床叙述中提取相关信息。机器学习(ML)工具最初是利用人口统计学和实验室数据来预测硫嘌呤的反应和不良反应,后来是生物疗法。因此,人工智能可以通过将患者病史、实验室值和成像报告综合为可操作的见解来支持临床决策。NLP算法可以比手工图表审查更有效地识别疾病表型、药物使用和不良事件,从而实现大规模流行病学研究和质量改进工作。利用大型机器学习模型合成大量的多组学数据,评估微生物组、遗传和转录数据是该领域当前和未来工作的重点。大型语言模型(llm)是人工智能应用的另一个方面,它可能会改变我们行医的方式。它们在诊所环境中被用来帮助综合病人遭遇和促进准确和简明的医疗记录。有各种各样的商业语音到文本解决方案可以记录患者与提供者的交互并生成文档,从而帮助减轻管理负担和提供者的倦怠。法学硕士也可以利用聊天机器人的形式来制定诊断和治疗结论。这些可以是耐心面对的,它们可以通过使用生成人工智能来帮助回答常见的患者问题。他们也可以面对提供者,在那里他们可以用来整理已发表的文献和指南,以帮助提出护理建议。在过去的几年里,这些技术有了爆炸式的发展,但对产出的深思熟虑的审查和周到的应用是防止这些计算机系统产生幻觉和产生错误数据的有害后果的关键。这些系统的用户必须意识到一些限制,以便理解它们的价值。内窥镜图像质量的变化、设备的差异以及标注标准的不一致都会影响人工智能系统的性能和通用性。许多IBD内窥镜下的AI研究显示出中度至高度的异质性,这限制了结果的可重复性和稳健性。大多数研究都是在有限的外部数据集的控制环境中进行的,这可能不能反映真实的临床环境。在临床环境中使用人工智能会引发伦理和法律问题,例如数据隐私、知情同意以及诊断错误时的责任。虽然人工智能在IBD中的前景是不可否认的,但广泛采用将需要强有力的验证、监管部门的批准,并融入临床工作流程。这些系统的开发人员需要承认已被识别和未被识别的偏见,以便以最安全的方式使用它们。重要的是,开发透明、可解释的人工智能模型对于确保临床医生的信任和道德部署至关重要。胃肠病学家、数据科学家和工程师之间的跨学科合作对于将这些创新从实验室转化为临床至关重要。 总之,人工智能有望通过提高诊断准确性、简化工作流程和支持个性化护理来重新定义IBD的管理。随着这些技术的成熟,它们不会取代临床医生,但无疑会增强临床决策——迎来IBD精准医疗的新时代。
{"title":"WEO Newsletter: The Impact of Artificial Intelligence on Management of Inflammatory Bowel Disease: An Expert Commentary","authors":"","doi":"10.1111/den.15072","DOIUrl":"https://doi.org/10.1111/den.15072","url":null,"abstract":"&lt;p&gt;By Nayantara Coelho-Prabhu, MD FACG AGAF FASGE, Mayo Clinic Rochester&lt;/p&gt;&lt;p&gt;The complexity of IBD, including both Crohn's disease (CD) and ulcerative colitis (UC), lies in its heterogeneity in presentation, unpredictable disease course, and varying responses to therapy. Current approaches rely on a combination of clinical indices, imaging, endoscopy, histology, and biomarkers—many of which are subjective and variably interpreted. This subjectivity results in difficulties with establishing standards of care, and often is the root cause of complications. Also, there is an increasing focus on achieving healing in IBD across all aspects of the disease including clinical, radiologic, endoscopic and histologic (STRIDE-II). To achieve this, we must establish standardization across these targets. These challenges present a fertile ground for AI applications aimed at improving accuracy, efficiency, and personalization in IBD management.&lt;/p&gt;&lt;p&gt;Endoscopic assessment remains central to IBD diagnosis and monitoring. However, the qualitative nature of inflammation scoring and interobserver variability in all scoring systems such as the Mayo Endoscopic Score or SES-CD has long plagued clinical and research settings. This has been the impetus to develop automated scoring systems that aim to standardize these scores. The first iteration of these models used still images to train convoluted neural networks (CNNs) and then reported on their successful scoring of test data still images. These systems utilized expert scoring as the gold standard, and they were found to have excellent performance in distinguishing Mayo 0-1 from Mayo 2-3 scores, similar to human experts. The next step was that CNNs were trained to read video segments, obtained from pharmaceutical randomized trials that had captured video segments, scored by central readers. Because the earlier systems were compared to human gold standard, which has low interoperator agreement, the next step in this evolution was to consider disease outcome as a measure of validity. Again, clinical trial videos were used and the CNNs were trained to report a cumulative disease score that was correlated with outcomes with more meaningful results. The goal is to be able to predict responders from non-responders. AI can detect subtle visual features on endoscopy, which can be harnessed to make histologic inference without the need for biopsy. Such predictive CNNs have been developed using white light images as well as enhanced imaging techniques including endocytoscopy, narrow band imaging (vascular patterns) and I-scan. These can predict relapse rates based on real-time endoscope imaging with great accuracy. In capsule enteroscopy, AI has been developed to accurately identify and quantify small bowel ulcerations, and significantly reduce capsule reading time, for both trainees and experts. These recent AI-driven computer vision tools have demonstrated the ability to automatically segment mucosal features, detect ulcera","PeriodicalId":159,"journal":{"name":"Digestive Endoscopy","volume":"37 7","pages":"807-809"},"PeriodicalIF":5.0,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/den.15072","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144598393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Novel Method for Effective Closure of Mucosal Defects After Endoscopic Full-Thickness Resection Using a Dual-Channel Endoscope 双通道内镜全层切除后有效闭合粘膜缺损的新方法。
IF 4.7 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-07-07 DOI: 10.1111/den.15080
Geng Qin, Guanyu Chen, Shiyu Du

Endoscopic full-thickness resection (EFTR) has emerged as a preferred therapeutic modality for the treatment of submucosal tumors, including gastrointestinal stromal tumors [1]. Despite its growing use, post-EFTR closure remains technically challenging due to difficulties in approximating and securing the mucosal edges [2, 3]. These challenges often hinder effective closure and increase the risk of complications.

To overcome these limitations, we have developed a novel closure technique employing a dual-channel endoscope, designed to facilitate precise and efficient wound approximation. The two working channels of the endoscope (GIF-2TQ26OM) are designated as Channel A and Channel B, with titanium clips deployed through each referred to as A-clips and B-clips, respectively.

During the closure procedure, only a single A-clip is used throughout. This clip is employed to grasp and retract the mucosa (or mucosa with the muscularis propria) from one side of the defect, aligning it linearly with the opposing edge (Figure 1B). Once proper alignment is achieved, one or more B-clips are applied to approximate the bilateral mucosal edges and secure the closure (Figure 1C,E). The A-clip is then released and repositioned to repeat the process on the next section of the defect (Figure 1D). After completing the placement of B-clips, the A-clip performs the final approximation to complete the closure. Figure 2 is an illustration.

This technique has been successfully applied in clinical practice, as demonstrated in the accompanying video (Video S1), confirming its feasibility and effectiveness in real-world EFTR cases.

The dual-channel endoscopic technique offers multiple advantages: improved mucosal alignment, reduced clip span, shorter procedural time, and enhanced surgical precision. Collectively, these benefits contribute to increased procedural efficiency and potentially lower complication rates.

Geng Qin designed and performed the research, collected and analyzed the data. Geng Qin and Shiyu Du offered funding support. Guanyu Chen drafted and revised the manuscript.

The authors declare no conflicts of interest.

内镜下全层切除(EFTR)已成为治疗粘膜下肿瘤(包括胃肠道间质瘤[1])的首选治疗方式。尽管eftr的使用越来越多,但由于难以接近和固定粘膜边缘,因此在技术上仍然具有挑战性[2,3]。这些挑战往往阻碍有效闭合,并增加并发症的风险。为了克服这些限制,我们开发了一种采用双通道内窥镜的新型闭合技术,旨在促进精确和有效的伤口近似。内窥镜(GIF-2TQ26OM)的两个工作通道指定为通道A和通道B,每个通道部署钛夹,分别称为A夹和B夹。在闭合过程中,整个过程中只使用一个a型夹。该夹用于从缺损一侧抓取并缩回粘膜(或粘膜与固有肌层),使其与对侧边缘线性对齐(图1B)。一旦达到正确的对齐,应用一个或多个b夹来接近双侧粘膜边缘并确保闭合(图1C,E)。然后释放a夹并重新定位,在缺陷的下一个部分重复该过程(图1D)。在完成b -clip的放置之后,A-clip执行最后的近似以完成闭包。图2是一个示例。该技术已成功应用于临床实践,如所附视频(视频S1)所示,证实了其在现实世界EFTR病例中的可行性和有效性。双通道内镜技术具有多种优势:改善粘膜对齐,缩短夹夹跨度,缩短手术时间,提高手术精度。总的来说,这些好处有助于提高手术效率并潜在地降低并发症发生率。Geng Qin设计并执行了研究,收集并分析了数据。秦赓和杜士宇提供了资金支持。陈冠宇起草并修改原稿。作者声明无利益冲突。
{"title":"A Novel Method for Effective Closure of Mucosal Defects After Endoscopic Full-Thickness Resection Using a Dual-Channel Endoscope","authors":"Geng Qin,&nbsp;Guanyu Chen,&nbsp;Shiyu Du","doi":"10.1111/den.15080","DOIUrl":"10.1111/den.15080","url":null,"abstract":"<p>Endoscopic full-thickness resection (EFTR) has emerged as a preferred therapeutic modality for the treatment of submucosal tumors, including gastrointestinal stromal tumors [<span>1</span>]. Despite its growing use, post-EFTR closure remains technically challenging due to difficulties in approximating and securing the mucosal edges [<span>2, 3</span>]. These challenges often hinder effective closure and increase the risk of complications.</p><p>To overcome these limitations, we have developed a novel closure technique employing a dual-channel endoscope, designed to facilitate precise and efficient wound approximation. The two working channels of the endoscope (GIF-2TQ26OM) are designated as Channel A and Channel B, with titanium clips deployed through each referred to as A-clips and B-clips, respectively.</p><p>During the closure procedure, only a single A-clip is used throughout. This clip is employed to grasp and retract the mucosa (or mucosa with the muscularis propria) from one side of the defect, aligning it linearly with the opposing edge (Figure 1B). Once proper alignment is achieved, one or more B-clips are applied to approximate the bilateral mucosal edges and secure the closure (Figure 1C,E). The A-clip is then released and repositioned to repeat the process on the next section of the defect (Figure 1D). After completing the placement of B-clips, the A-clip performs the final approximation to complete the closure. Figure 2 is an illustration.</p><p>This technique has been successfully applied in clinical practice, as demonstrated in the accompanying video (Video S1), confirming its feasibility and effectiveness in real-world EFTR cases.</p><p>The dual-channel endoscopic technique offers multiple advantages: improved mucosal alignment, reduced clip span, shorter procedural time, and enhanced surgical precision. Collectively, these benefits contribute to increased procedural efficiency and potentially lower complication rates.</p><p>Geng Qin designed and performed the research, collected and analyzed the data. Geng Qin and Shiyu Du offered funding support. Guanyu Chen drafted and revised the manuscript.</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":159,"journal":{"name":"Digestive Endoscopy","volume":"37 10","pages":"1123-1124"},"PeriodicalIF":4.7,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/den.15080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Digestive Endoscopy
全部 Geobiology Appl. Clay Sci. Geochim. Cosmochim. Acta J. Hydrol. Org. Geochem. Carbon Balance Manage. Contrib. Mineral. Petrol. Int. J. Biometeorol. IZV-PHYS SOLID EART+ J. Atmos. Chem. Acta Oceanolog. Sin. Acta Geophys. ACTA GEOL POL ACTA PETROL SIN ACTA GEOL SIN-ENGL AAPG Bull. Acta Geochimica Adv. Atmos. Sci. Adv. Meteorol. Am. J. Phys. Anthropol. Am. J. Sci. Am. Mineral. Annu. Rev. Earth Planet. Sci. Appl. Geochem. Aquat. Geochem. Ann. Glaciol. Archaeol. Anthropol. Sci. ARCHAEOMETRY ARCT ANTARCT ALP RES Asia-Pac. J. Atmos. Sci. ATMOSPHERE-BASEL Atmos. Res. Aust. J. Earth Sci. Atmos. Chem. Phys. Atmos. Meas. Tech. Basin Res. Big Earth Data BIOGEOSCIENCES Geostand. Geoanal. Res. GEOLOGY Geosci. J. Geochem. J. Geochem. Trans. Geosci. Front. Geol. Ore Deposits Global Biogeochem. Cycles Gondwana Res. Geochem. Int. Geol. J. Geophys. Prospect. Geosci. Model Dev. GEOL BELG GROUNDWATER Hydrogeol. J. Hydrol. Earth Syst. Sci. Hydrol. Processes Int. J. Climatol. Int. J. Earth Sci. Int. Geol. Rev. Int. J. Disaster Risk Reduct. Int. J. Geomech. Int. J. Geog. Inf. Sci. Isl. Arc J. Afr. Earth. Sci. J. Adv. Model. Earth Syst. J APPL METEOROL CLIM J. Atmos. Oceanic Technol. J. Atmos. Sol. Terr. Phys. J. Clim. J. Earth Sci. J. Earth Syst. Sci. J. Environ. Eng. Geophys. J. Geog. Sci. Mineral. Mag. Miner. Deposita Mon. Weather Rev. Nat. Hazards Earth Syst. Sci. Nat. Clim. Change Nat. Geosci. Ocean Dyn. Ocean and Coastal Research npj Clim. Atmos. Sci. Ocean Modell. Ocean Sci. Ore Geol. Rev. OCEAN SCI J Paleontol. J. PALAEOGEOGR PALAEOCL PERIOD MINERAL PETROLOGY+ Phys. Chem. Miner. Polar Sci. Prog. Oceanogr. Quat. Sci. Rev. Q. J. Eng. Geol. Hydrogeol. RADIOCARBON Pure Appl. Geophys. Resour. Geol. Rev. Geophys. Sediment. Geol.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1